Dr. Moussa Diawara, Dr. Jeff Smith, Dr. Libby Stuty, Ms. Amy Uhernik
Cannabidiol (CBD) is a form of cannabinoid that lacks the psychoactive (hight) effect associated with Tetrahydrocannabinol (THC), the primary cannabinoid found in cannabis. Research findings point to CBD as a possible memory-enhancing agent that could be used to treat cognitive disorders of L&M whereas treatment of PTSD might not be an appropriate, or neurodegenerative disease of L&M like Alzheimer’s.
We hypothesize that CBD is a modulator of human L&M. Our broad objective is to examine the potential effect of CBD on human L&M in relatively large scale surveys and in isolation from other confounding factors (i.e., other drugs being specifically combined with CBD or particular preexisting medical conditions). We specifically aim to determine whether CBD, when administered alone to healthy human subjects is a modulator of human L&M, and aim to determine whether particular demographic factors present in the general population (e.g., starting age of cannabis use, race, gender, smoking, mental health status, SSRI (or other drug use) will affect the modulatory effect of CBD on L&M.